Shares of CureVac CVAC,
it gained 7.7% in trading on Friday after the company said it plans to develop COVID-19 vaccine candidates that prevent infection with new modifications as part of an agreement with the UK. The UK has already agreed to take 50 million doses of the yet-to-be-recognized variable vaccines. CureVac, which currently has the COVID-19 trial vaccine in Phase 3 clinical trials in partnership with Bayer AG BAYN,
they said they hope to put new variable vaccine candidates in clinical trials at CureVac UK this week also announced a research partnership with GlaxoSmithKline GSK,
to develop new COVID-19 vaccines that provide protection against some of the emerging variants of the virus. CureVac stock is up 134.2% over the past three months, and the S&P 500 SPX,
has acquired 12.4%.